Basal-bolus therapy with insulin degludec improves long-term glycaemic control with less nocturnal hypoglycaemia compared with insulin

被引：0
|
作者：
Russell-Jones, D. L. [1 ,2 ]
Francisco, A. O. [3 ]
Pei, H. [4 ]
Heller, S. R. [5 ]
机构：
[1] Royal Surrey Cty Hosp, Guildford, Surrey, England
[2] Univ Surrey, Guildford GU2 5XH, Surrey, England
[3] Novo Nordisk AS, Soborg, Denmark
[4] Novo Nordisk Inc, Princeton, NJ USA
[5] Univ Sheffield, Sch Med & Biosci, Sheffield S10 2TN, S Yorkshire, England
来源：
DIABETOLOGIA | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1045
引用
收藏
页码：S425 / S425
页数：1
相关论文
共 50 条
  • [21] Glycaemic control with insulin glulisine versus regular human insulin in a basal-bolus regimen in patients with Type 2 diabetes
    Dailey, G
    Rosenstock, J
    Moses, R
    Ways, K
    DIABETOLOGIA, 2004, 47 : A265 - A266
  • [22] Efficacy of Insulin Degludec as Basal-Bolus Therapy After Switching from Insulin Glargine or Insulin Detemir in Young Persons with Type 1 Diabetes
    Urakami, Tatsuhiko
    Habu, Masako
    Okuno, Misako
    Suzuki, Junichi
    Takahashi, Shori
    DIABETES, 2014, 63 : A323 - A323
  • [23] Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin
    De Leeuw, I
    Vague, P
    Selam, JL
    Skeie, S
    Lang, H
    Draeger, E
    Elte, JWF
    DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 73 - 82
  • [24] Intensification of basal insulin therapy with step-wise addition of insulin aspart boluses compared with basal-bolus therapy: the FullSTEP study
    Rodbard, H.
    Visco, V. E.
    Andersen, H.
    Hiort, L. C.
    Shu, D. H. W.
    DIABETOLOGIA, 2013, 56 : S412 - S412
  • [25] Switching to basal-bolus insulin therapy is effective and safe in long-term type 2 diabetes patients inadequately controlled with other insulin regimens
    Vinagre, Irene
    Sanchez-Hernandez, Juan
    Luis Sanchez-Quesada, Jose
    Angel Maria, Miguel
    de Leiva, Alberto
    Peres, Antonio
    ENDOCRINOLOGIA Y NUTRICION, 2013, 60 (05): : 249 - 253
  • [26] The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial
    Billings, Liana K.
    Agner, Bue F. Ross
    Altuntas, Yuksel
    Gron, Randi
    Halladin, Natalie
    Klonoff, David C.
    Tentolouris, Nikolaos
    Jodar, Esteban
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2021, 15 (03): : 636 - 645
  • [27] Improvement in the glycaemic control of patients after switching from human insulin to insulin glargine-based basal-bolus regimen
    Nagy Erzsebet
    Kovacs Gabor
    ORVOSI HETILAP, 2018, 159 (29) : 1201 - 1207
  • [28] Insulin Degludec: Reduction of Hypoglycemia during Basal-Bolus Therapy in Patients with Diabetes Mellitus Type 1 or 2
    Luedemann, J.
    Merker, L.
    Milek, K.
    Kaiser, M.
    Wilhelm, B.
    DIABETOLOGIE UND STOFFWECHSEL, 2013, 8 (01) : 35 - 42
  • [29] Evaluation of the Short-Term Cost-Effectiveness of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus Therapy in the USA
    Billings, Liana K.
    Mocarski, Michelle
    Slothuus, Ulla
    Hunt, Barnaby
    Valentine, William
    Jodar, Esteban
    DIABETES, 2017, 66 : A254 - A255
  • [30] Faster-acting insulin aspart vs insulin aspart as part of basal-bolus therapy improves postprandial glycaemic control in uncontrolled type 2 diabetes: the onset® 2 trial
    Bowering, K.
    Case, C.
    Harvey, J.
    Reeves, M.
    Sampson, M.
    Strzinek, R.
    Bretler, D. -M.
    Bang, R. B.
    Bode, B. W.
    DIABETOLOGIA, 2016, 59 : S399 - S400
12345